Literature DB >> 14585082

Central effects of the somatotropic system.

Harald Jörn Schneider1, Uberto Pagotto, Günter Karl Stalla.   

Abstract

The somatotropic axis interacts with the central nervous system (CNS) on several levels. Growth hormone (GH) and insulin-like growth factor-I (IGF-I) receptors are expressed in many brain areas including the hippocampus, pituitary and hypothalamus. GH and IGF-I can pass the blood-brain barrier by an as yet not completely understood mechanism. They can also be produced in the brain and thus act via paracrine/autocrine mechanisms. GH and IGF-I are important factors in the development and differentiation of the CNS and have protective properties in dementia, and in traumatic and ischemic injury of the CNS. An improvement in cognitive functioning in GH-deficient patients by GH substitution has been shown. Significant results could, however, only be achieved with supraphysiological doses. In some studies, a correlation between IGF-I and cognitive function in the elderly has been found. GH has an important impact on mood and well-being with GH secretory capacity being reduced in depression. Pulsatile GH secretion is closely related to slow wave sleep (SWS) with SWS being stimulated by GH releasing hormone and rapid eye movement (REM) sleep by GH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585082     DOI: 10.1530/eje.0.1490377

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  24 in total

1.  Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy.

Authors:  N P Maric; M Doknic; D Pavlovic; S Pekic; M Stojanovic; M Jasovic-Gasic; V Popovic
Journal:  J Endocrinol Invest       Date:  2010-05-17       Impact factor: 4.256

Review 2.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 3.  Epilepsy, depression, and growth hormone.

Authors:  Tracy Butler; Patrick Harvey; Lila Cardozo; Yuan-Shan Zhu; Adam Mosa; Emily Tanzi; Fahad Pervez
Journal:  Epilepsy Behav       Date:  2019-02-14       Impact factor: 2.937

4.  A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans.

Authors:  Johannes D Veldhuis; Martin Bidlingmaier; Joy Bailey; Dana Erickson; Paola Sandroni
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

Review 5.  GH deficiency as the most common pituitary defect after TBI: clinical implications.

Authors:  Vera Popovic
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 6.  Growth hormone deficiency in the transition period: body composition and gonad function.

Authors:  G Balercia; L Giovannini; F Paggi; M Spaziani; N Tahani; M Boscaro; A Lenzi; A Radicioni
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

7.  Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?

Authors:  Alberto Fernandez; Niki Karavitaki; Olaf Ansorge; Violet Fazal-Sanderson; John A H Wass
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Cre-mediated recombination in pituitary somatotropes.

Authors:  Igor O Nasonkin; Mary Anne Potok; Sally A Camper
Journal:  Genesis       Date:  2009-01       Impact factor: 2.487

9.  Microstructural brain changes in acromegaly: quantitative analysis by diffusion tensor imaging.

Authors:  R Kilicarslan; M M Ilhan; A Alkan; A Aralasmak; M E Akkoyunlu; L Kart; E Tasan
Journal:  Br J Radiol       Date:  2014-04-16       Impact factor: 3.039

10.  Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study.

Authors:  C Sievers; P G Sämann; T Dose; C Dimopoulou; D Spieler; J Roemmler; J Schopohl; M Mueller; H J Schneider; M Czisch; H Pfister; G K Stalla
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.